- Home
- IBRX vs CDE Comparison
IBRX vs CDE Comparison
Compare IBRX & CDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- CDE
- Stock Information
- Founded
- IBRX 2014
- CDE 1928
- Country
- IBRX United States
- CDE United States
- Employees
- IBRX N/A
- CDE N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- CDE Precious Metals
- Sector
- IBRX Health Care
- CDE Basic Materials
- Exchange
- IBRX Nasdaq
- CDE Nasdaq
- Market Cap
- IBRX 2.4B
- CDE 2.6B
- IPO Year
- IBRX N/A
- CDE N/A
- Fundamental
- Price
- IBRX $2.81
- CDE $6.21
- Analyst Decision
- IBRX Buy
- CDE Strong Buy
- Analyst Count
- IBRX 2
- CDE 4
- Target Price
- IBRX $17.38
- CDE $7.81
- AVG Volume (30 Days)
- IBRX 5.6M
- CDE 8.7M
- Earning Date
- IBRX 11-12-2024
- CDE 11-06-2024
- Dividend Yield
- IBRX N/A
- CDE N/A
- EPS Growth
- IBRX N/A
- CDE N/A
- EPS
- IBRX N/A
- CDE N/A
- Revenue
- IBRX $7,332,000.00
- CDE $1,010,652,000.00
- Revenue This Year
- IBRX $2,572.99
- CDE $32.61
- Revenue Next Year
- IBRX $747.59
- CDE $39.85
- P/E Ratio
- IBRX N/A
- CDE N/A
- Revenue Growth
- IBRX 1218.71
- CDE 31.38
- 52 Week Low
- IBRX $2.82
- CDE $2.42
- 52 Week High
- IBRX $10.53
- CDE $7.72
- Technical
- Relative Strength Index (RSI)
- IBRX 29.17
- CDE 44.06
- Support Level
- IBRX $2.82
- CDE $6.14
- Resistance Level
- IBRX $3.18
- CDE $7.38
- Average True Range (ATR)
- IBRX 0.28
- CDE 0.29
- MACD
- IBRX -0.23
- CDE -0.05
- Stochastic Oscillator
- IBRX 1.25
- CDE 10.00
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada Mexico, and North America.